findmyKOL

Vasanth Vedantham, MD, PhD

Basic profile

University of California, San Francisco

ORCIDNPI
RegionSan Francisco, CA · WestSpecialtyClinical Cardiac ElectrophysiologyFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH funding2007–2026

Vasanth Vedantham is a Cardiology physician affiliated with University of California, San Francisco. OpenAlex indexes 115 publications with 7,797 citations (h-index 27); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
115publications

Distinct works indexed by OpenAlex, matched via ORCID.

7,797citations

Total citations across indexed works.

27h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
4NIH grants · 2007–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

505 Parnassus Ave
Box 0124
San Francisco, CA 941430124

Telephone

415-353-2873

Registry record last updated 5 May 2008.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    60%
    Factor Xa inhibitor60%
    Eliquis88%Xarelto12%
    Part D<11 patients
  • Cardiovascular

    40%
    Beta blocker27.3%
    Metoprolol Succinate100%
    Part D19 patients
    Antiarrhythmic12.7%
    Flecainide Acetate57%Mexiletine Hcl43%
    Part D<11 patients
Where care is delivered (Part B)86.5% facility · 13.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

4 NIH research awards on record, funded 20072026 per NIH RePORTER. The latest:

8 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”